Cytoplasmic and nuclear programmed death ligand 1 expression in peritumoral stromal cells in breast cancer: Prognostic and predictive value

Table 2 Distribution of patients with programmed cell death protein 1 ligand 1-positive lymphocyte score < 3 and ≥ 3, n (%)

Breast cancer characteristics	PDCD1 LG1+ LF score		P value χ² tests
	< 3	≥ 3
T stage
Т in situ	0 (0)	4 (100)	0.50
Т1в	2 (18.2)	9 (81.8)
Т1с	27 (30.3)	62 (69.7)
Т2	12 (27.3)	32 (72.7)
N stage
N0	16 (19.7)	65 (80.3)	0.03
N1	19 (40.4)	28 (59.6)
N2	6 (37.5)	10 (62.5)
N3	0 (0)	4 (100)
Tumor grade (G)
G1	6 (37.5)	10 (62.5)	0.47
G2	26 (28.6)	65 (71.4)
G3	9 (21.9)	32 (78.1)
Lymphovascular invasion
No	18 (21.4)	66 (78.6)	0.05
Yes	23 (35.9)	41 (64.1)
Perineural invasion
No	31 (27.0)	84 (73.0)	0.70
Yes	10 (30.3)	23 (69.7)
ER status
Negative	3 (18.7)	13 (81.3)	0.39
Positive	38 (28.8)	94 (71.2)
PR status
Negative	15 (36.6)	2 (63.4)	0.13
Positive	26 (24.3)	81 (75.7)
HER2 status
HER2-	39 (30.5)	89 (69.5)	0.05
HER2+	2 (10.0)	18 (90.0)
Molecular biological subtype
Luminal A	18 (32.1)	38 (67.9)	0.26
Luminal B HER2-	20 (30.3)	46 (69.7)
Luminal B HER2+	0 (0)	10 (100)
Non-luminal HER2+	2 (20.0)	8 (80.0)
TNBC	1 (16.7)	5 (83.3)

ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2; PR: Progesterone receptor; TNBC: Triple negative breast cancer; PDCD1 LG1: Programmed cell death protein 1 ligand 1.